A Phase Ⅰ/Ⅱ, Multicenter, Single-arm, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0
研究概览
简要总结
This study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participants (A maximum of 15 participants will be enrolled in each of the United States and China) will be enrolled and dosed with EHT102. The dose-escalation phase (Phase I) includes two predefined dose cohorts (3 participants per cohort), with sequential enrollment from low to high dose. During dose escalation, each participant will receive a unilateral EHT102 injection followed by safety observation.
详细描述
The low-dose and high-dose cohorts will be followed by a 28-day DLT observation period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prior to study participation, participants and/or their legal guardians must provide informed consent for this trial, voluntarily sign the written informed consent form (ICF), and commit to completing all protocol-specified follow-up visits;
- •Participants must be able to communicate effectively with investigators and comply with study requirements, with guardian assistance if needed. For young children without developed language skills, guardians must ensure cooperation with investigator instructions;
- •Participants and/or their legal guardians must demonstrate adequate comprehension of the trial's nature and maintain realistic expectations regarding potential benefits.
- •Pediatric patients (male or female) aged ≥ 1 and ≤ 17 years at the time of inclusion ;
- •Genetic testing report indicates DFNB9 congenital deafness with Biallelic mutations in the Otoferlin gene;
- •Severe or profound hearing loss (≥65 dB) assessed by ABR, with the sentinel participant having an ABR >90 dB;
- •Meet eligibility criteria for otologic surgery: Absence of middle/inner ear malformations, cochleovestibular nerve abnormalities, or active otologic inflammation as confirmed by computed tomography (CT) and/or magnetic resonance imaging (MRI) within 3 months or during screening period, with surgical suitability determined by the investigator;
- •DPOAE testing shows present response.
排除标准
- •Have other types of hearing loss ineligible for otologic surgery, including but not limited to:
- •Middle/inner ear malformations or developmental abnormalities identified by CT/MRI within 3 months; Hearing loss caused by cochleovestibular nerve abnormalities; Conductive hearing loss ; Mixed hearing loss; Syndromic deafness with malformations.
- •Have pre-existing otologic conditions deemed by the investigator to potentially compromise the planned surgery or interfere with study endpoint evaluation, including but not limited to:
- •Acute/chronic otitis media;; Ménière's disease; Acoustic neuroma; Unresolved sudden sensorineural hearing loss.
- •Have a history of drug abuse.
- •Have a history of receiving any known ototoxic medications (e.g., aminoglycosides, cisplatin, loop diuretics) within the past 6 months.
- •Antiviral/immunotherapy within 3 months prior to screening.
- •Administration of any live-attenuated vaccines within 30 days prior to screening.
- •Have immunocompromised status or immunodeficiency disorders, including but not limited to:
- •Positive HIV antibody (HIV Ab) test; Congenital or acquired immunodeficiency (investigator-determined contraindication to immunosuppressants) ; History of organ transplantation.
- •Have severe systemic diseases or acute conditions, including but not limited to:
- •Active tuberculosis; Active herpes zoster infection; Pancreatitis; Renal insufficiency; Gastrointestinal ulcers.
- •Have contraindications to surgery or anesthesia as determined by the surgeon, anesthesiologist, or designated personnel, including but not limited to:
- •History of cardiovascular or cerebrovascular events within the past 6 months (e.g., myocardial infarction, heart failure, angina, stroke, or transient ischemic attack) Any other cardiac conditions deemed unsuitable for study participation by the investigator; Known hypersensitivity to the investigational drug.
- •Have participated in gene therapy trials within 6 months prior to screening, plan to participate in other interventional clinical trials within one year post-treatment, or have received investigational drugs within 5 half-lives of the last dose from previous trials.
- •Have implantable devices (e.g., cochlear implants) in the target ear at screening.
- •Have other severe congenital disorders.
- •Have a history of neurological/psychiatric disorders (e.g., epilepsy, dementia).
- •Have chronic anticoagulant therapy that cannot be temporarily discontinued.
- •Have a history of radiotherapy/chemotherapy deemed by investigators to potentially affect trial outcomes.
- •Have tested positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis C virus (HCV) antibody with HCV RNA positive, or positive for human immunodeficiency virus (HIV) antibody, or have active syphilis (TPPA positive and RPR positive).
- •Females of childbearing potential with positive pregnancy tests prior to dosing; Females of childbearing potential and non-sterilized males with fertile partners unwilling/unable to use effective contraception from ICF signing until ≥24 months post-dosing.
- •Any other condition that, at the discretion of the investigator, renders the participant unsuitable for enrollment.
研究组 & 干预措施
The low-dose cohort
Participants will receive a single unilateral or bilateral administration of EHT102 at the defined low dose level
干预措施: EHT102 Injection (Drug)
The high-dose cohort
Participants will receive a single unilateral or bilateral administration of EHT102 at the defined high dose level.
干预措施: EHT102 Injection (Drug)
结局指标
主要结局
Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0
时间窗: Up to week 52
Safety will be evaluated by summarizing the number and percentage of participants experiencing treatment-related adverse events (TEAEs) and serious adverse events (SAEs). Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and graded for severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
Proportion of Participants Achieving a Hearing Sensitivity Threshold of ≤70 dB by behavioral audiometry
时间窗: Up to week 26
This endpoint evaluates the efficacy of EHT102 injection by calculating the percentage of participants who achieve a hearing sensitivity threshold of ≤70 dB in the treated ear, as assessed by behavioral audiometry.
次要结局
- Change from Baseline in Auditory Brainstem Response (ABR) Thresholds(Week 4, Week 13, Week 26, and Week 52)
- Change from baseline in auditory steady state response (ASSR) thresholds(Week 4, 13, 26, and 52)
- Proportion of Participants of a hearing sensitivity threshold of ≤70 dB assessed by behavioral audiometry(Week 4, 13 and 52)
- Proportion of Participants of a hearing sensitivity threshold of ≤45 dB assessed by behavioral audiometry at Week 26 post injection(Week 26)